Allogene upgraded at Citizens on discounted EPS, revenue...

2026-01-09 14:59:08 ET More on Allogene Therapeutics Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript Allogene signals pivotal ALPHA3 interim data and ALLO-329 proof-of-concept in first half 2026 while maintaining cash runway into H2 2027 Allogene Therapeutics GAAP EPS of -$0.19 beats by $0.03 Seeking Alpha's Quant Rating on Allogene Therapeutics Read the full article on Seeking Alpha For further details see: Allogene upgraded at Citizens on discounted EPS, revenue multiple